CD4 and inflammatory bowel disease: In LPL, there was also no difference between IBD patients and controls in the expression of these immunoinhibitory molecules in either FOXP3+ subset of CD4+ T cells, as they were expressed by the majority of both iTregs and nTregs in most subjects.